| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
8 companies
New Enterprise Associates 14, L.P. is a 10% Owner at ADAPY with holdings across 8 companies. Recent SEC Form 4 filings include 1 buy and 34 sells.
Estimated insider holdings value: $194.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 694,551 | $1.08 | $751,255.76 | -11.3% | +3.6% | +378.8% | |
| Jan 25, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 134,558 | $1.50 | $202,208.87 | -1.3% | -4.0% | +180.0% | |
| Jan 20, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 26,555 | $1.83 | $48,725.97 | -0.3% | -20.9% | +130.5% | |
| Jan 14, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 21,550 | $1.94 | $41,826.49 | -0.2% | -46.4% | +130.9% | |
| Jan 11, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 18,760 | $2.07 | $38,739.78 | -0.2% | -50.7% | +117.7% | |
| Jan 6, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 31,916 | $2.26 | $72,188.58 | -0.3% | -47.9% | +118.6% | |
| Jan 3, 2022 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 116,476 | $2.29 | $266,870.49 | -1.1% | -32.4% | +63.5% | |
| Dec 29, 2021 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 67,427 | $2.37 | $159,499.83 | -0.6% | -14.4% | +75.5% | |
| Dec 23, 2021 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Sell | 291,152 | $2.36 | $688,499.19 | -0.7% | -19.7% | +69.9% | |
| Mar 16, 2020 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Buy | 475,000 | $16.00 | $7,600,000.00 | +13.4% | - | - |